Marinus Pharmaceuticals (MRNS) PT Set at $19.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $19.00 price objective on Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on MRNS. Zacks Investment Research cut Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, November 2nd. BidaskClub cut Marinus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, October 9th. ValuEngine upgraded Marinus Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, October 16th. Finally, Mizuho restated a buy rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $19.67.

Marinus Pharmaceuticals stock opened at $5.17 on Tuesday. Marinus Pharmaceuticals has a 12 month low of $3.31 and a 12 month high of $10.54.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Monday, October 29th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.06). Analysts anticipate that Marinus Pharmaceuticals will post -0.93 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its position in Marinus Pharmaceuticals by 9.8% during the third quarter. BlackRock Inc. now owns 2,910,405 shares of the biopharmaceutical company’s stock valued at $29,103,000 after acquiring an additional 259,793 shares during the last quarter. Jennison Associates LLC increased its position in Marinus Pharmaceuticals by 0.8% during the second quarter. Jennison Associates LLC now owns 2,757,356 shares of the biopharmaceutical company’s stock valued at $19,495,000 after acquiring an additional 21,733 shares during the last quarter. Partner Fund Management L.P. purchased a new stake in Marinus Pharmaceuticals during the third quarter valued at $17,741,000. Credit Suisse AG increased its position in Marinus Pharmaceuticals by 673.8% during the third quarter. Credit Suisse AG now owns 1,033,326 shares of the biopharmaceutical company’s stock valued at $10,334,000 after acquiring an additional 899,780 shares during the last quarter. Finally, VHCP Management III LLC purchased a new stake in Marinus Pharmaceuticals during the third quarter valued at $6,723,000. Institutional investors own 68.70% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

See Also: Asset Allocation

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply